Ovarian Cancer Trial, Recruiting NCT06817174 Sponsor: Imperial College Healthcare NHS Trust Condition: Ovarian Cancer
Back to Ovarian Cancer

Ovarian Cancer Trial, Recruiting

NCT06817174
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 years or older
  • People with suspected or confirmed advanced ovarian cancer (at a stage known as FIGO 3B or higher)
  • People whose doctors are considering active cancer treatment, either surgery first followed by chemotherapy, or chemotherapy first followed by surgery
  • People who have had a CT scan (a specific type called a portal venous phase CT) taken before any surgery or cancer treatment begins
  • People whose cancer can be seen clearly on that CT scan, with visible disease measuring at least 2cm

Who may not be able to join:

  • People who have a known medical reason why they cannot have a CT scan with contrast dye injected into a vein — for example, a dye allergy, kidney failure, or being unable to lie flat
  • People who are not able to give informed consent
  • People who are known to be pregnant
  • People whose cancer cannot be seen clearly on the CT scan, or where the visible disease measures less than 2cm
  • People who have previously had surgery to remove an ovarian or fallopian tube mass (adnexal mass)
  • People whose CT scan images are significantly affected by interference — for example, from metal implants — making it impossible to properly analyse the visible disease
  • People who are only well enough for palliative (comfort-focused) care at the time they first present for treatment

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: (+44) +44 (0)20 3313 3274

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Imperial College Healthcare NHS Trust
Registry
ClinicalTrials.gov
Start date
10 February 2025
Est. completion
1 January 2032

Where this trial is recruiting

🇬🇧 United Kingdom

Primary endpoints

Comparison of CT-based Radiomics Models and Clinical Model in Predicting Progression-Free Survival Post-Cytoreductive Surgery in Ovarian Cancer

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov